{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:41:57Z","timestamp":1789731717036,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"AstraZeneca, Wilmington, DE"},{"name":"Amgen, Thousand Oaks, CA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s12325-023-02514-0","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T11:02:10Z","timestamp":1685098930000},"page":"2944-2964","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy of Biologics in Severe, Uncontrolled Asthma Stratified by Blood Eosinophil Count: A Systematic Review"],"prefix":"10.1007","volume":"40","author":[{"given":"Stephanie","family":"Korn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa J.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7785-6881","authenticated-orcid":false,"given":"Jean-Pierre","family":"Llanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4175-7336","authenticated-orcid":false,"given":"Christopher S.","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"key":"2514_CR1","unstructured":"Asthma UK. Severe asthma: the unmet need and the global challenge. 2017. https:\/\/www.asthma.org.uk\/globalassets\/get-involved\/external-affairs-campaigns\/publications\/severe-asthma-report\/auk_severeasthma_2017.pdf. Accessed 8 Nov 2022."},{"key":"2514_CR2","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention 2022. https:\/\/ginasthma.org\/wp-content\/uploads\/2022\/07\/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf. Accessed 8 Nov 2022."},{"key":"2514_CR3","doi-asserted-by":"publisher","first-page":"1800703","DOI":"10.1183\/13993003.00703-2018","volume":"52","author":"T Volmer","year":"2018","unstructured":"Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018;52:1800703.","journal-title":"Eur Respir J"},{"key":"2514_CR4","doi-asserted-by":"publisher","first-page":"1701486","DOI":"10.1183\/13993003.01486-2017","volume":"50","author":"A Bourdin","year":"2017","unstructured":"Bourdin A, Molinari N, Vachier I, Pahus L, Suehs C, Chanez P. Mortality: a neglected outcome in OCS-treated severe asthma. Eur Respir J. 2017;50:1701486.","journal-title":"Eur Respir J"},{"key":"2514_CR5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/all.14221","volume":"75","author":"I Agache","year":"2020","unstructured":"Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75:1023\u201342.","journal-title":"Allergy"},{"key":"2514_CR6","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/14728222.2020.1783242","volume":"24","author":"GM Gauvreau","year":"2020","unstructured":"Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24:777\u201392.","journal-title":"Expert Opin Ther Targets"},{"key":"2514_CR7","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","volume":"388","author":"JM FitzGerald","year":"2016","unstructured":"FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128\u201341.","journal-title":"Lancet"},{"key":"2514_CR8","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","volume":"187","author":"NA Hanania","year":"2013","unstructured":"Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187:804\u201311.","journal-title":"Am J Respir Crit Care Med"},{"key":"2514_CR9","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","volume":"384","author":"A Menzies-Gow","year":"2021","unstructured":"Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384:1800\u20139.","journal-title":"N Engl J Med"},{"key":"2514_CR10","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486\u201396.","journal-title":"N Engl J Med"},{"key":"2514_CR11","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","volume":"4","author":"HG Ortega","year":"2016","unstructured":"Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4:549\u201356.","journal-title":"Lancet Respir Med"},{"key":"2514_CR12","unstructured":"PRISMA guidelines. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). 2020. http:\/\/www.prisma-statement.org\/. Accessed 29 July 2021."},{"key":"2514_CR13","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention 2020. https:\/\/ginasthma.org\/wp-content\/uploads\/2020\/04\/GINA-2020-full-report_-final-_wms.pdf. Accessed 26 July 2021."},{"key":"2514_CR14","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1056\/NEJMoa1704064","volume":"377","author":"J Corren","year":"2017","unstructured":"Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377:936\u201346.","journal-title":"N Engl J Med"},{"key":"2514_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12931-019-1056-4","volume":"20","author":"CM Prazma","year":"2019","unstructured":"Prazma CM, Bel EH, Price RG, Bradford ES, Albers FC, Yancey SW. Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis. Respir Res. 2019;20:83.","journal-title":"Respir Res"},{"key":"2514_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"2514_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"2514_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","volume":"388","author":"S Wenzel","year":"2016","unstructured":"Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388:31\u201344.","journal-title":"Lancet"},{"key":"2514_CR19","doi-asserted-by":"publisher","first-page":"00204-2019","DOI":"10.1183\/23120541.00204-2019","volume":"6","author":"M Castro","year":"2020","unstructured":"Castro M, Rabe KF, Corren J, Pavord ID, Katelaris CH, Tohda Y, et al. Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma. ERJ Open Res. 2020;6:00204-2019.","journal-title":"ERJ Open Res"},{"key":"2514_CR20","unstructured":"ClinicalTrials.gov. Evaluation of dupilumab in patients with persistent asthma: LIBERTY ASTHMA QUEST (study results data). https:\/\/clinicaltrials.gov\/. Accessed 29 July 2021."},{"key":"2514_CR21","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","volume":"388","author":"ER Bleecker","year":"2016","unstructured":"Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115\u201327.","journal-title":"Lancet"},{"key":"2514_CR22","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","volume":"9","author":"TW Harrison","year":"2021","unstructured":"Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med. 2021;9:260\u201374.","journal-title":"Lancet Respir Med"},{"key":"2514_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/JAA.S190221","volume":"12","author":"S O'Quinn","year":"2019","unstructured":"O\u2019Quinn S, Xu X, Hirsch I. Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma. J Asthma Allergy. 2019;12:21\u201333.","journal-title":"J Asthma Allergy"},{"key":"2514_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","volume":"6","author":"JM FitzGerald","year":"2018","unstructured":"FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018;6:51\u201364.","journal-title":"Lancet Respir Med"},{"key":"2514_CR25","doi-asserted-by":"publisher","first-page":"1800936","DOI":"10.1183\/13993003.00936-2018","volume":"52","author":"ER Bleecker","year":"2018","unstructured":"Bleecker ER, Wechsler ME, FitzGerald JM, Menzies-Gow A, Wu Y, Hirsch I, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018;52:1800936.","journal-title":"Eur Respir J"},{"key":"2514_CR26","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1080\/03007995.2017.1347091","volume":"33","author":"M Goldman","year":"2017","unstructured":"Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies. Curr Med Res Opin. 2017;33:1605\u201313.","journal-title":"Curr Med Res Opin"},{"key":"2514_CR27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:355\u201366.","journal-title":"Lancet Respir Med"},{"key":"2514_CR28","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","volume":"184","author":"M Castro","year":"2011","unstructured":"Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184:1125\u201332.","journal-title":"Am J Respir Crit Care Med"},{"key":"2514_CR29","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","volume":"5","author":"GL Chupp","year":"2017","unstructured":"Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5:390\u2013400.","journal-title":"Lancet Respir Med"},{"key":"2514_CR30","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198\u2013207.","journal-title":"N Engl J Med"},{"key":"2514_CR31","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651\u20139.","journal-title":"Lancet"},{"key":"2514_CR32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.rmed.2019.04.008","volume":"151","author":"SW Yancey","year":"2019","unstructured":"Yancey SW, Bradford ES, Keene ON. Disease burden and efficacy of mepolizumab in patients with severe asthma and blood eosinophil counts of\u00a0\u2265150\u2013300 cells\/\u00b5L. Respir Med. 2019;151:139\u201341.","journal-title":"Respir Med"},{"key":"2514_CR33","doi-asserted-by":"publisher","first-page":"190137","DOI":"10.1183\/16000617.0137-2019","volume":"29","author":"M Bonini","year":"2020","unstructured":"Bonini M, Di Paolo M, Bagnasco D, Baiardini I, Braido F, Caminati M, et al. Minimal clinically important difference for asthma endpoints: an expert consensus report. Eur Respir Rev. 2020;29:190137.","journal-title":"Eur Respir Rev"},{"key":"2514_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14728222.2020.1783242","volume":"24","author":"GM Gauvreau","year":"2020","unstructured":"Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24:1\u201316.","journal-title":"Expert Opin Ther Targets"},{"key":"2514_CR35","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","volume":"9","author":"S Diver","year":"2021","unstructured":"Diver S, Khalfaoui L, Emson C, Wenzel SE, Menzies-Gow A, Wechsler ME, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9:1299\u2013312.","journal-title":"Lancet Respir Med"},{"key":"2514_CR36","doi-asserted-by":"publisher","first-page":"2101296","DOI":"10.1183\/13993003.01296-2021","volume":"59","author":"A Sverrild","year":"2022","unstructured":"Sverrild A, Hansen S, Hvidtfeldt M, Clausson CM, Cozzolino O, Cerps S, et al. The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM). Eur Respir J. 2022;59:2101296.","journal-title":"Eur Respir J"},{"key":"2514_CR37","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa1402895","volume":"370","author":"GM Gauvreau","year":"2014","unstructured":"Gauvreau GM, O\u2019Byrne PM, Boulet L-P, Wang Y, Cockcroft D, Bigler J, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370:2102\u201310.","journal-title":"N Engl J Med"},{"key":"2514_CR38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nri3786","volume":"15","author":"JV Fahy","year":"2015","unstructured":"Fahy JV. Type 2 inflammation in asthma\u2014present in most, absent in many. Nat Rev Immunol. 2015;15:57\u201365.","journal-title":"Nat Rev Immunol"},{"key":"2514_CR39","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1172\/JCI95693","volume":"128","author":"EM Dunican","year":"2018","unstructured":"Dunican EM, Elicker BM, Gierada DS, Nagle SK, Schiebler ML, Newell JD, et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest. 2018;128:997\u20131009.","journal-title":"J Clin Invest"},{"key":"2514_CR40","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","volume":"50","author":"BN Lambrecht","year":"2019","unstructured":"Lambrecht BN, Hammad H, Fahy JV. The cytokines of asthma. Immunity. 2019;50:975\u201391.","journal-title":"Immunity"},{"key":"2514_CR41","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3389\/fphar.2019.01387","volume":"10","author":"G Marone","year":"2019","unstructured":"Marone G, Granata F, Pucino V, Pecoraro A, Heffler E, Loffredo S, et al. The intriguing role of interleukin 13 in the pathophysiology of asthma. Front Pharmacol. 2019;10:1387.","journal-title":"Front Pharmacol"},{"key":"2514_CR42","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.pupt.2009.12.005","volume":"23","author":"YD Gao","year":"2010","unstructured":"Gao YD, Zou JJ, Zheng JW, Shang M, Chen X, Geng S, et al. Promoting effects of IL-13 on Ca2+ release and store-operated Ca2+ entry in airway smooth muscle cells. Pulm Pharmacol Ther. 2010;23:182\u20139.","journal-title":"Pulm Pharmacol Ther"},{"key":"2514_CR43","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","volume":"154","author":"NA Hanania","year":"2011","unstructured":"Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154:573\u201382.","journal-title":"Ann Intern Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02514-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02514-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02514-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T05:17:31Z","timestamp":1686806251000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02514-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["2514"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02514-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]},"assertion":[{"value":"6 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}